Last
Update:
December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
XX International AIDS Conference
|
-
Ultra-deep
pyrosequencing analysis of HBV quasispecies diversity in residual HBV
viremia on tenofovir-based cART
J. Audsley, M. Littlejohn, S.J. Bent, et al
Abstract
-
Tenofovir-containing regimens are associated with increased mortality in
patients with lower CD4 levels in a Ugandan cohort
J. Gonzalez Perez, J. Ikapule, S. Kawooya, et al
Abstract
-
Tenofovir urinary
output is associated with renal tubular dysfunction in HIV-positive patients
A. Calcagno, L. Marinaro, M. Simiele, et al
Abstract
-
Tenofovir-containing regimens are associated with increased mortality in
patients with lower CD4 levels in a Ugandan cohort
J. Gonzalez Perez, J. Ikapule, S. Kawooya, et al
Abstract
-
Development of a
novel formulation of tenofovir disoproxyl fumarate (TDF) to increase
bioavailability and reduce dose for treatment of HIV/AIDS in emerging
markets
M. Watkins, S. Wring, R. Randolph2 P. Domanico
Abstract
-
Low body weight
and tenofovir use are risk factors for renal dysfunction in Vietnamese
HIV-infected patients in a prospective observational cohort for 2 years
between 2011 and 2013
D. MizusAbstracthima1,,
J. Tanuma, N.T. Lam, et al
-
Renal function
decline and associated risk factors among patients treated with
tenofovir-based first line anti-retroviral regimen in public sector in
Myanmar
Y.N. Aung, A. Thida1 K.K.K. Win, et al
HIV-associated risk behaviour among injecting drug users
participating in an HIV pre-exposure prophylaxis trial in Bangkok,
Thailand
S. Vanichseni, M. Martin, P. Suntharasamai, et al
Poster
Abstract
POSTER
Tenofovir plasma concentrations related with creatinine clearance
changes particularly in association with LPV/r in first-line
regimen of African patients in Cameroon and Senegal: ANRS 12115
DAYANA sub-study
G. Peytavin, S. Koulla-Shiro2, P. Lê Minh, et al
Poster
Abstract
A WEEK-IN-REVIEW FEATURED REPOR
POSTER
Factors influencing plasma tenofovir
concentrations in HIV adults: effect of low body weight, chronic
hepatitis C and proximal tubular dysfunction
N. Thammajaruk, J. Sophonphan, R.A. Ramautarsing, et al
Poster
-Abstract
POSTER
Predictors of renal
insufficiency in patients randomized to second-line lopinavir/ritonavir
monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir
J. Sophonphan, P. Chetchotisakd, W. Munsakul, et al
Poster
Abstract
POSTER
Impact of tenofovir (TDF)-containing antiretroviral treatment (ART)
modifications to other anti-hepatitis B virus (HBV) regimens in patients
co-infected with HIV-HBV
A. Boyd, J. Gozlan, S. Maylin, et al
Poster
Abstract
The
Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in
Thailand: participant adherence and study results
K. Choopanya, S. Vanichseni, P.
Suntharasama1m, et al
Abstract
Predictors of daily tenofovir exposure in Thai subjects taking
protease inhibitor-based combination antiretroviral therapy
S.J. Kerr, N. Thammajaruk, A. Colbers, et al
Abstract
Characterization of a new use for acyclovir and tenofovir using
human cervico-vaginal tissue ex vivo
C. Vanpouile, A. Introini, A. Lisco, et al
Comparison of adherence with pre-exposure prophylaxis among
HIV-1-negative clinical trial participants in serodiscordant
relationships in Kisumu before and after release of the trial
results
B. Wamuti, J. Odoyo, B. Rono, et al
Abstract
Tenofovir
nephrotoxicity in resource-limited setting of western India:
higher rate of renal function decline, acute kidney injury and
progression to chronic kidney disease compared to western data
A. Dravid, A. Sadre, S. Dhande,et al
Abstract
Pregnancy
incidence and birth outcomes among African women in a clinical
trial of pre-exposure prophylaxis: the Partners PrEP Study
N. Mugo, T. Hong, C. Celum, et al
Abstract
Decline in serum 25-OH vitamin D levels in HIV-hepatitis B virus
(HBV) co-infected patients with after long term antiretroviral
therapy
T. Apornpong, R.A. Ramautarsing, S. Ubolyam,et al
Abstract
Transient or low-level replication is common in HIV-HBV
co-infected patients treated with long-term tenofovir
A. Boyd, P. Miailhes, C. Lascoux-Combe, et al
Abstract
Modelling
HIV PrEP in humanized mice: pharmacokinetic studies on
antiretroviral drugs raltegravir, tenofovir and maraviroc
R. Akkina, M. Veselinovic C.P.
Neff,et al
Abstract
XIX International AIDS Conference
|
POSTER
Tenofovir associated proximal renal tubular dysfunction in
HIV-positive children and adolescents
A. Camacho-Gonzalez, L. Greenbaum, R. Chakraborty, et al
Poster
Abstract
POSTER
Prevalence and factors associated with renal dysfunction in HIV
positive and negative adults at the University Teaching Hospital, in Lusaka
J. Banda, A. Mweemba, S. Siziya, et al
Poster
Abstract
POSTER
Tenofovir-associated kidney function decline with a PI-based
versus NNRTI-based regimen
A. Abraham, B. Lau, M. Estrella, et al
Poster
Abstract
POSTER
Lessons from the rapid response of Namibia's supply chain when antiretroviral
treatment guidelines changed to
tenofovir-based first-line regimen
J. Lates, B. Ongeri, A. Wolde,et al
Poster
Abstract
POSTER
Scaling-up of triggered viral load in rural Zimbabwe: implications
for phasing out of D4T
S. Van Den Broucke, S. Simons, K. Kranzer, et al
Poster
Abstract
POSTER
Participant adherence in the Bangkok Tenofovir Study, an HIV
pre-exposure prophylaxis trial in Bangkok
M. Martin1,, S. Vanichseni, P. Suntharasamai, et al
Poster
Abstract
POSTER
Morbidity and mortality of injecting drug users participating in
the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial
in Thailand
S. Vanichseni , M. Martin, P. Suntharasamai, et
al
Poster
Abstract
Absence of clinically
relevant drug interaction between delamanid, a new drug for multidrug-resistant
tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects
A. Paccaly, C. Petersen , S.
Patil, et al
Abstract
Tenofovir disoproxil fumarate (TDF) pharmacokinetics (PK) with daily
dosing in the first week of life (HPTN 057)
K. Nielsen-Saines, M. Mirochnick, N. Kumwenda, et al
Abstract
Tenofovir plasma
pharmacokinetics in AIDS clinical trials group study A5202
C. Venuto,, Q. Ma, E. Daat. et al
Abstract
Changing patterns
of NRTI and PI resistance mutations between 2006 and 2011 in >1,200
ART-experienced South African patients:
association with
the introduction of tenofovir (TDF) and abacavir (ABC) and with the cumulative
effects of LPV/r therapy
G. van Zyl, M. Claassen, S. Engelbrecht, et
al
Abstract
Method of hormonal
contraception is associated with lower tenofovir concentration in healthy
women (MTN-001):
implications for
pre-exposure prophylaxis
J. Coleman, A. Chaturvedula, C. Hendrix, et al
Abstract
Method of hormonal
contraception is associated with lower tenofovir concentration in healthy women
(MTN-001):
implications for pre-exposure prophylaxis
J. Coleman, A. Chaturvedula, C. Hendrix, et al
Abstract
Prevalence of
hepatitis B co-infection and response to antiretroviral therapy among
HIV-positive patients
in urban Tanzania
C. Hawkins, B. Christian, J. Ye, et al
Abstract
Transition from
stavudine to tenofovir and zidovudine for first-line treatment of HIV/AIDS in
low- and middle-income countries
E. Dancel, P. Ashigbie
Abstract
Associations of inflammatory markers with AIDS and non-AIDS
clinical events after initiation of
antiretroviral therapy (ART): AIDS Clinical Trials Group A5224s, a
substudy of ACTG A5202P
G.A. McComsey, D. Kitch, P.E. Sax, et al
Abstract
Changing patterns of
NRTI and PI resistance mutations between 2006 and 2011 in >1,200 ART-experienced
South African patients: association with the introduction of tenofovir (TDF) and
abacavir (ABC) and
with the cumulative effects of LPV/r therapy
G. van Zyl, M. Claassen, S. Engelbrecht, et al
Abstract
Absence of renal and bone toxicity in non-clinical studies of BMS-986001, a
nucleoside reverse transcriptase inhibitor (NRTI)
of human
immunodeficiency virus (HIV)
M. Guha, G. Pilcher, J. Moehlenkamp, et al
Abstract
Incidence of acute kidney injury from tenofovir disoproxil fumarate (TDF) in
human immunodeficiency virus (HIV) positive patients
at Chiang Mai
University (CMU) hospital
P. Kannika, N. Nuntachit, R. Chaiwarith, et
al
Abstract
Model
projections of the population-level impact, on HIV and herpes simplex virus
type-2 (HSV-2)
and cost-effectiveness of tenofovir gel, an antiretroviral microbicide
A. Foss, F. Terris-Prestholt, A. Cox, et al
Abstract
Sustained release tenofovir and maraviroc from intravaginal ring in sheep
T.J. Smith
Abstract
Development of a new intravaginal ring technology for the extended delivery of
the microbicide tenofovir
with and without the contraceptive levonorgestrel
T. Johnson, M. Clark, J. Clark, et al
Abstract
HCV/HIV
co-infection and the degree of liver fibrosis as risk factors of
HAART-associated nephrotoxicity
M. del Palacio, A. Moreno, M. Martínez-Colubi,
et al
Abstract
Women
Initiated Solution to Prevent HIV/AIDS (The WISH Study): factors associated with
intentions
to use microbicides
and tenofovir
S. Kandathil, S.M. Harvey, D. Champeau, et al
Abstract
Enrollment of women into a large randomized trial of HIV pre-exposure
prophylaxis: screening data from the VOICE (vaginal and oral interventions to
prevent HIV) study (MTN-003)
Z.M. Chirenje, VOICE (MTN 003) Study Team
Abstract
Demographic, behavioural and clinical characteristics of women enrolled into the
VOICE (Vaginal and Oral Interventions
to Prevent HIV) study (MTN-003)
J. Marrazzo, VOICE (MTN 003) Study Team
Abstract
Evaluation of four tenofovir-containing regimens as first-line
treatments in Cameroon and Senegal:
the DAYANA Trial, IMEA032/ANRS12115
R. Landman, S. Koulla-Shiro, P.-S. Sow, et al
Poster
Abstract
POSTER
Key considerations for successful implementation of the 2010 PMTCT
guidelines in Rwanda - tenofovir (TDF) based highly active
antiretroviral treatment (HAART) extended during breastfeeding
regimens in Rwanda
I. Ange Anitha, S.U. Nadine, N. Jean Pierre, et al
Poster
Abstract
POSTER
Differences in renal function and toxicity between
antiretroviral-naive and experienced HIV-infected patients
initiating a tenofovir containing regimen
P. Wikman, M. Pérez-Elías, P. Safont, et al
Poster
Abstract
POSTER
A prospective study of changes in serum lipid profile among people
living with HIV/AIDS on PI based second line ART regimen
R. De, S. Bhandari, M. Mahato, et al
Poster
Abstract
POSTER
Substituting drugs within first-line regimen at hospitals and
health centers: an observational cohort assessment in rural
Lesotho
N.D. Labhardt, M. Sello, J. Ehmer, et al
Poster
Abstract
POSTER
Impact of tenofovir-associated renal dysfunction among
HIV-infected patients with low body-weight: a retrospective cohort
study of the Japanese patients
T. Nishijima, H. Komatsu, H. Gatanaga, et al
Poster
Abstract
POSTER
Enrollment, follow-up, and risk behavior of injecting drug users
in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis
trial
in Bangkok, Thailand
K. Choopanya, S. Vanichseni, P. Suntharasamai, et al
Poster
Abstract
POSTER
Morbidity and mortality of injecting drug users participating in
the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial
in
Bangkok, Thailand
S. Vanichseni, M. Martin, P. Suntharasamai, et al
Poster
Abstract
POSTER
Antiretroviral drugs and incidence of chronic kidney disease, ANRS
CO3 Aquitaine cohort (2004-2008)
P. Morlat, A. Vivot, F. Dauchy, et al
Poster
Abstract
Virological efficacy of the four tenofovir-containing
WHO-recommended regimens for initial antiretroviral therapy
M. Tang, P. Kanki, R. Shafer, et al
Abstract
Explaining the CAPRISA 004 results: tenofovir as a double-targeted
HIV-1/HSV-2 antiviral
A. Graciela, A. Lisco, C. Vanpouille, et al
Abstract
Preventing
HIV and herpes infections: predicting the impact of the CAPRISA
tenofovir gel in KwaZulu-Natal, South Africa
D.J. Gerberry, B.G. Wagner, J.G. Garcia-Lerma, et al
Abstract
Case-controlled study of Fanconi syndrome (FS) in HIV-infected
patients receiving tenofovir DF (TDF)
S. Gupta, C. Wyatt, A. Rachlis. et al
Abstract
Changes
in natural killer cell activation and function in early HIV
infection
V. Naranbhai, M. Altfeld, L. Werner, et al
Abstract
In vivo
inhibition of HIV-1 infection at mucosal sites by an anti-HIV CCR5
targeting vector: potential use as an HIV microbicide
J. Walker, J. McGee, G. Bauer. et al
Abstract
Potent
HBV therapy and availability of laboratory monitoring fail to
abrogate increased risk of death in HBV-HIV-co-infected
individuals
in the
DART study
H. Price, R. Gilson, D. Pillay, et al
Abstract
Strengthening health systems for HIV prevention: integrating
quality improvement and family planning services with 1% tenofovir
gel
provision
in the CAPRISA 008 phase IIIB randomized controlled implementation
trial
K. Torjesen, K. Mate, L. Mansoor, et al
Abstract
Acute
pre-seroconversion HIV infection at baseline prior to starting
oral or topical pre-exposure prophylaxis: iPrEx and CAPRISA 004
R. Grant, Q. Abdool Karim, T. Liegler, et al
Abstract
Ultra-short cycles of quadruple anti reverse transcriptase
combinations, 2 days or 1 day a week, as effective maintenance
treatment in
HIV-1
infection
J.P.L. Leibowitch, D. Mathez, P. de Truchis, et al
Abstract
Evaluating different strategies for transitioning patients from
stavudine to tenofovir in resource-constrained settings
P. Grant, A. Talbot, E. Bendavid, et al
Abstract
Novel
pattern of treatment-emergent lipid and renal abnormalities in
antiretroviral naïve patients in the multi-centre Canadian
Observational
Cohort (CANOC)
K. Johns, M. Harris, D. Milan, et al
Abstract
Evolution
of kidney tubular dysfunction (KTD) in a prospective cohort of
HIV+ patients on prolonged exposure to tenofovir
P. Labarga, P. Barreiro, S. Rodriguez-Novoa, et al
Abstract
Determination of kidney function prior to tenofovir initation:
four-fold difference in need of tenofovir dose reduction depending
on method used
C. Mony Kim, T. Phe, T. Sopheak, et al
Abstract
Incidence
and prevalence of serum hypophosphatemia in a large cohort of
HIV-infected patients
M. del Palacio, J.M. Rodríguez, A. Moreno, et al
Abstract
Risk of
antiretroviral-associated renal toxicity in HIV\-infected
patients with altered basal renal function
P. Safont
Gasó, P. WIkman, M. del Palacio, et al
Abstract
Risk
factors for K65R development in mexican patients failing to
multiple antiretroviral (ARV) combinations
F.Y. García Kishi, E. Vidal-Laurencio, W. Moncada, et al
Abstract
11th International Workshop on Clinical
Pharmacology
of HIV Infection |
Impact
of age on renal function in patients receiving tenofovir
L. Goeddel, K.W. Crawford, R. Moore, et al
PDF ABSTRACT
Tenofovir disoproxil fumarate (TDF) pharmacokinetics (PK) with increased doses
in HIV-1
infected pregnant women and their newborns (HPTN 057)
M. Mirochnick, N. Kumwenda, E. Joao, et al
PDF ABSTRACT
Tenofovir population pharmacokinetics in HIV-infected children and adolescents
J. King, R. Yogev, A. Wiznia, et al
5th
International AIDS Society (IAS) Conference on
HIV
Pathogenesis, Treatment and Prevention |
POSTER
Rates and reasons for antiretroviral therapy substitutions/discontinuations in
patients
treated with tenofovir-based first HAART
A. Ammassari, M.P. Trotta, P. Lorenzini, et al
PDF Poster
Abstract
Tenofovir-based
regimens associated with less NRTI drug resistance mutations among patients
failing first-line
antiretroviral therapy in Nigeria
M. Etiebet, L. Eyzaguirre, J. Shepherd, et al
Abstract
Renal safety of
tenofovir disoproxil fumarate in a cohort of patients with advanced hepatic
fibrosis/cirrhosis
and HIV infection
G. Cologni, F. Gatti, M. Puoti, et al
Abstract
Net cost of
switching from stavudine to tenofovir in first line antiretroviral therapy in
Zambia
S. Rosen, K. Mccoy, A. Mazimba, et al
Abstract
Reversibility of
tenofovir-related renal toxicity
K. Wever, M.A. van Agtmael, A. Carr, et al
Abstract
Ninth International Congress on Drug Therapy in HIV Infection
|
Ortu F, Piano P, Serra P, et al
Abstract
A cross-sectional
comparison of renal function in patients on stable abacavir (ABC) or tenofovir
(TDF)
containing therapy
Waters LJ, Randell P, Jackson AGA, et al
Abstract
Once-daily (OD)
TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate
substitution:
efficacy, tolerability and adherence
Esser S, Staszewski S, Haberl AE, et al
Abstract
Changes in
hematological parameters after switching treatment of HIV-infected patients from
zidovudine to
abacavir or tenofovir DF
Viergever RF, Berg MJ, van Solinge WW, et al
Abstract
The safety and efficacy
of tenofovir DF in combination with lamivudine and efavirenz in
antiretroviral-naïve patients
through 7 years
Madruga JVR, Cassetti I, Etzel A, et al
Abstract
Impact on bone
mineral density of tenofovir-containing HAART in HIV-1 infected children and
adolescents:
a report from 5 years of clinical experience
Rosso R, Di Biagio A, Parodi A, et al
Abstract
Tenofovir
toxicity in children: two clinical cases
Bengleil AS, Kambraki M, Al Fituri, et al
Abstract
|
ARV Drugs Main Page
Main
New/Newsworthy
